“As use of CGM grows, especially for people with type 2 diabetes, the missing element of insulin titration needs to be satisfied,” said Glytec’s Chief Medical Officer and diabetologist, Dr. Andrew S. Rhinehart. “This is where Glytec enters the picture. Our ability to seamlessly interact with glucose data that’s captured through CGM and use it to personalize insulin therapy is how patients are going to see real results, real improvements. Training tens of thousands of primary care providers on how to interpret and act on CGM data is a daunting proposition. Our platform can obviate that need, offering primary care providers the means to use CGM data to formulate timely and discrete dosing recommendations in a highly efficient, effective and scalable manner.”
The new USPTO patent allowance awarded to Glytec depicts the following key systems and methods [highly abridged and consolidated]:
- A dosing controller comprising data processing hardware in communication with memory hardware obtains glucose data for a patient from either: (A) a continuous glucose monitoring system in communication with a patient device, or (B) a remote computing device that executes a program for downloading the data from a glucometer or continuous glucose monitoring system. Such data includes glucose measurements and times associated with those measurements, among other attributes.
- A dosing controller transmits a recommended meal bolus dose of insulin to a patient via: (A) an administration device (e.g., smart insulin pen, insulin pump or other) in communication with a patient device, or (B) a patient device that executes a mobile application configured to transmit the recommended meal bolus dose of insulin to an administration device. The mobile application may also be configured to display on a screen of the patient device the number of carbohydrates consumed by the patient during a selected time interval. Additionally, the administration device may be configured to automatically dial in and administer the number of units of insulin for the recommended meal bolus.
“A lot of new diabetes technologies have been introduced over the past decade, but the percentage of people with type 2 diabetes who are at goal has not improved,” said Glytec Senior Vice President of Research & Development Robby Booth. “We believe a connected, virtual care model that capitalizes on these new technologies and makes the data truly actionable— as described in this latest patent allowance as well as earlier patent allowances— will serve as a catalyst for sustained A1C reduction, increased time in range and other outcomes improvements. CGM, smart insulin pens and insulin pumps all play an important role, and Glytec’s insulin titration and medication optimization capabilities are designed to support and enhance them whether they’re being used in an outpatient or inpatient setting.”
Founded in 2006, Glytec is the pioneer of digital therapeutics, improving the lives of people with diabetes by making insulin a more effective and accessible option for millions unable to achieve their treatment goals. The company’s patented eGlycemic Management System is the only U.S. Food and Drug Administration-cleared software-as-a-medical-device (SaMD) platform to enable the mass personalization of insulin across the continuum of care: inpatient, outpatient and virtual settings alike. Glytec offers several programs combining evidence-based decision support technologies with expert professional services proven to aid providers in achieving best practices and standardization while reducing hyperglycemia, hypoglycemia, A1C, readmissions, length of stay and cost. The company has offices in Waltham, Mass., and Greenville, S.C.